Last reviewed · How we verify
Metastatic Breast Cancer Progression Post-Antiestrogen Therapy
Approved treatments
- Faslodex · Translational Oncology Research International
- Faslodex · AstraZeneca
Faslodex works by binding to and degrading the estrogen receptor, preventing it from promoting the growth of cancer cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Metastatic Breast Cancer Progression Post-Antiestrogen Therapy patent landscape — cliff calendar, originator estates, attackable patents
- Metastatic Breast Cancer Progression Post-Antiestrogen Therapy treatment landscape brief
- Metastatic Breast Cancer Progression Post-Antiestrogen Therapy treatment updates RSS
Frequently asked questions about Metastatic Breast Cancer Progression Post-Antiestrogen Therapy
What drugs treat Metastatic Breast Cancer Progression Post-Antiestrogen Therapy?
Tracked treatments include Faslodex.
What is the treatment for Metastatic Breast Cancer Progression Post-Antiestrogen Therapy?
Standard treatment for Metastatic Breast Cancer Progression Post-Antiestrogen Therapy includes Faslodex. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Metastatic Breast Cancer Progression Post-Antiestrogen Therapy patent cliff · Metastatic Breast Cancer Progression Post-Antiestrogen Therapy CI report
- Treatment: Faslodex · Translational Oncology Research International
- Treatment: Faslodex · AstraZeneca
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing